PPAR γ agonists and the future for insulin sensitizers: A report of a debate and presentations on the subject at the 72nd Scientific Sessions of the American Diabetes Association, Philadelphia, 8-12 June, 2012

British Journal of Diabetes and Vascular Disease

Volumn 12, Issue 4, 2012, Pages 206-210

  Henry, Robert R ^a   Erickson, Deborah ^b   Ciaraldi, Theodore P ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEGLITAZAR; INSULIN SENSITIZING AGENT; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE;

BLADDER CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC PATIENT; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG RECEPTOR BINDING; DRUG SAFETY; FRACTURE; GLYCEMIC CONTROL; HEART FAILURE; HEART PROTECTION; HUMAN; MEDICAL DECISION MAKING; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRESCRIPTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84866488527     PISSN: 14746514     EISSN: 17534305     Source Type: Journal    
DOI: 10.1177/1474651412459202     Document Type: Conference Paper

References (23)

1. Bailey CJ, Day C. Thiazolidinediones today. Br J Diabetes Vasc Dis. 2001 ; 1: 7-13
2. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med. 1999 ; 16: 179-92
3. Bailey CJ. The rise and fall of troglitazone. Diabet Med. 2000 ; 17: 414-5
4. Nissen SE, Wolski K, Topol EJ. Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. JAMA. 2005 ; 294: 2581-2586
5. Conlon D. Goodbye glitazars?. Br J Diabetes Vasc Dis. 2006 ; 6: 135-137
6. Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med. 2007 ; 356: 2457-2471
7. Goldberg RB, Kendall DM, Deeg MA, et al. A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia. Diabetes Care. 2005 ; 28: 1547-54
8. Lincoff A, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials. JAMA. 2007 ; 298: 1180-88
9. NissenSE. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM224741.pdf
10. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone. JAMA. 2010 ; 304: 411-18
11. Lewis JD, Ferrara A, PengHedderson M, et al. FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. Diabetes Care. 2011 ; 34: 916-22
12. Mamtani R, Haynes K, Bilker WB, et al. Long-term therapy with thiazolidinediones and the risk of bladder cancer: A cohort study. ASCO. 2012 ;:
13. Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK. Thiazolidinedione Use and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2010 ; 95: 592-600
14. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012 ; 35: 278-80
15. Dormuth CR, Carney G, Carleton B, et al. Thiazolidinediones and Fractures in Men and Women. Arch Intern Med. 2009 ; 169: 1395-1402
16. Zinman B, Haffner SM, Herman WH, et al. ADOPT Study Group. Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes. J Clin Endocrinol Metab. 2010 ; 95: 134
17. van Lierop A H, Hamdy N A T, van der Meer R W, et al. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J Endocrinol. 2012 ; 166: 711-16
18. Staels B. The clinical significance of PPAR ?± and γ agonism. Br J Diabetes Vasc Dis. 2002 ; 2 (suppl 1). S28-31
19. McDonald WG, Cavey GS, Cole SL, et al. Identification of a Mitochondrial Target of Thiazolidinediones (mTOT). Diabetes. 2012 ; 61 ( suppl 1 ):
20. Poster session presented at: Clinical Diabetes and Therapeutics. American Diabetes Association 72nd Annual Meeting ; Philadelphia, PA ;..
21. Bricker D, Taylor E, Schell J, et al. A Mitochondrial Pyruvate Carrier Required for Pyruvate Uptake in Yeast, Drosophila, and Humans. Science. 337: 6090 96-100
22. Herzig S, Raemy E, Montessuit S, et al. Identification and Functional Expression of the Mitochondrial Pyruvate Carrier. Science. 337: 6090 93-96
23. Colca JR, VanderLugt JT, Adams WJ, et al. Clinical proof of concept with a prototype mTOT modulating insulin sensitizer. Diabetes. 2012 ; 61 ( suppl 1 ):